SCYNEXIS, Inc. Increase (Decrease) in Contract with Customer, Liability
SCYNEXIS, Inc. (SCYX) reported Increase (Decrease) in Contract with Customer, Liability of -$1.42 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2025-03-12
- SCYNEXIS, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-12-31 was -$770.00K.
- SCYNEXIS, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-09-30 was -$59.00K.
- SCYNEXIS, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-06-30 was -$179.00K.
- SCYNEXIS, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-03-31 was -$410.00K.
- SCYNEXIS, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was -$1.42M.
- SCYNEXIS, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$6.51M.
- SCYNEXIS, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$5.30M.
- SCYNEXIS, Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was -$1.73M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$770.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$829.00K derived: sum of 2 quarters · filed 2025-03-12 | -$1.01M derived: sum of 3 quarters · filed 2025-03-12 | -$1.42M 10-K · filed 2025-03-12 |
| 2024-09-30 | -$59.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$238.00K derived: sum of 2 quarters · filed 2024-11-06 | -$648.00K 10-Q · filed 2024-11-06 | -$3.35M derived: sum of 4 quarters · filed 2025-03-12 |
| 2024-06-30 | -$179.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$589.00K 10-Q · filed 2024-08-08 | -$3.29M derived: sum of 3 quarters · filed 2025-03-12 | -$4.97M derived: sum of 4 quarters · filed 2025-03-12 |
| 2024-03-31 | -$410.00K 10-Q · filed 2024-05-08 | -$3.12M derived: sum of 2 quarters · filed 2025-03-12 | -$4.79M derived: sum of 3 quarters · filed 2025-03-12 | -$5.90M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-12-31 | -$2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$4.38M derived: sum of 2 quarters · filed 2025-03-12 | -$5.49M derived: sum of 3 quarters · filed 2025-03-12 | -$6.51M 10-K · filed 2025-03-12 |
| 2023-09-30 | -$1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$2.78M derived: sum of 2 quarters · filed 2024-11-06 | -$3.81M 10-Q · filed 2024-11-06 | -$5.38M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$2.13M 10-Q · filed 2024-08-08 | -$3.71M derived: sum of 3 quarters · filed 2024-08-08 | -$4.82M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$1.02M 10-Q · filed 2024-05-08 | -$2.60M derived: sum of 2 quarters · filed 2024-05-08 | -$3.72M derived: sum of 3 quarters · filed 2024-05-08 | -$5.16M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$2.69M derived: sum of 2 quarters · filed 2024-03-28 | -$4.14M derived: sum of 3 quarters · filed 2024-03-28 | -$5.30M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$2.56M derived: sum of 2 quarters · filed 2023-11-13 | -$3.72M 10-Q · filed 2023-11-13 | -$5.05M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$2.60M 10-Q · filed 2023-08-14 | -$3.93M derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$1.16M 10-Q · filed 2023-05-10 | -$2.48M derived: sum of 2 quarters · filed 2023-05-10 | ||
| 2021-12-31 | -$1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$1.73M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | -$403.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |